South San Francisco, CA —September 24, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="https://amphivena.com/wp-content/uploads/2019-Amphivena-presentation-S877_Safety_and_Clinical_Activity_AMV564_Roboz_EHA_2019-Presentation.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=“"][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...